CYP19A1 polymorphisms and bladder cancer risk in the Chinese Han population

REFERENCES

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–590. doi: 10.1097/CM9.0000000000002108
   PubMed Web of Science ®Google Scholar
• Lobo N, Afferi L, Moschini M, et al.. Epidemiology, Screening, and Prevention of Bladder Cancer. European urology oncology. 2022;5(6):628–639. doi: 10.1016/j.euo.2022.10.003
   PubMedGoogle Scholar
• Clark KR. Bladder cancer: types, risk factors, diagnosis, and treatment. Radiol Technol. 2022;94(1):46–50.
   PubMedGoogle Scholar
• Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–795. doi: 10.1016/j.eururo.2018.09.001
   PubMed Web of Science ®Google Scholar
• Khadhouri S, Gallagher KM, MacKenzie KR et al. The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. BJU Int, 128(4), 440–450 (2021).
   PubMed Web of Science ®Google Scholar
• Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. Jama, 324(19), 1980–1991 (2020).
   PubMed Web of Science ®Google Scholar
• Koutros S, Kiemeney LA, Pal Choudhury P, et al. Genome-wide association study of bladder cancer reveals new biological and translational insights. Eur Urol. 2023;84(1):127–137. doi: 10.1016/j.eururo.2023.04.020
   PubMed Web of Science ®Google Scholar
• Qu W, Zhang F, Cheng Y, et al. The impact of genetic variants in the CYP2C8 gene on bladder cancer susceptibility. Front Endocrinol (Lausanne). 2022;13:989030. doi:10.3389/fendo.2022.989030
   PubMedGoogle Scholar
• Wang X, Guo Z, Zhu H, et al. Genetic variants in splicing factor genes and susceptibility to bladder cancer. Gene. 2022;809:146022. doi: 10.1016/j.gene.2021.146022
   PubMedGoogle Scholar
• Molehin D, Rasha F, Rahman RL, et al. Regulation of aromatase in cancer. Mol Cell Biochem. 2021;476(6):2449–2464. doi:10.1007/s11010-021-04099-0
   PubMedGoogle Scholar
• Parween S, DiNardo G, Baj F, et al. Differential effects of variations in human P450 oxidoreductase on the aromatase activity of CYP19A1 polymorphisms R264C and R264H. J Steroid Biochem Mol Biol. 2020;196:105507. doi:10.1016/j.jsbmb.2019.105507
   PubMedGoogle Scholar
• Bafligil C, Thompson DJ, Lophatananon A, et al. Association between genetic polymorphisms and endometrial cancer risk: a systematic review. J Med Genet. 2020;57(9):591–600. doi: 10.1136/jmedgenet-2019-106529
   PubMed Web of Science ®Google Scholar
• Wang T, Sun Y, Xiong Z et al. Association of ST6GAL1 and CYP19A1 polymorphisms in the 3’-UTR with astrocytoma risk and prognosis in a Chinese Han population. BMC Cancer, 21(1), 391 (2021).
   PubMedGoogle Scholar
• Kim RY, Sunkara KP, Bracke KR et al. A microRNA-21-mediated SATB1/S100A9/NF-κB axis promotes chronic obstructive pulmonary disease pathogenesis. Sci Transl Med, 13(621), eaav7223 (2021).
   PubMedGoogle Scholar
• Cai S, Feng Y, Ye J, et al. The prognostic roles of CYP19A1 expression in bladder cancer patients of different genders. Transl Androl Urol. 2021;10(9):3579–3590. doi: 10.21037/tau-21-400
   PubMedGoogle Scholar
• Yang Y, Wang P. Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population. Lipids Health Dis. 2020;19(1):187. doi:10.1186/s12944-020-01366-9
   PubMed Web of Science ®Google Scholar
• Cai Q, Zheng J, Bai M et al. Genetic Variations of CYP19A1 Gene and Stroke Susceptibility: A Case-Control Study in the Chinese Han Population. J Cardiovasc Pharmacol, 75(4), 344–350 (2020).
   PubMedGoogle Scholar
• Wu S, Ye J, Wang Z, et al.. Expression of aromatase in tumor related stroma is associated with human bladder cancer progression. Cancer biology & therapy. 2018;19(3):175–180. doi: 10.1080/15384047.2017.1414762
   PubMed Web of Science ®Google Scholar
• Nguyen DP, O’Malley P, Awamlh BAHA, Furrer M-A, Mongan NP. Association of Aromatase With Bladder Cancer Stage and Long-Term Survival: New Insights Into the Hormonal Paradigm in Bladder Cancer. Clin Genitourin Cancer, 15(2), 256–262 (2017).
   PubMedGoogle Scholar
• Moorthy HK, Prabhu GGL, Venugopal P. Clinical and therapeutic implications of sex steroid hormone receptor status in urothelial bladder cancer. Indian J Urol. 2020;36(3):171–178. doi:10.4103/iju.IJU_320_19
   PubMedGoogle Scholar
• Ide H, Miyamoto H. Sex hormone receptor signaling in bladder cancer: a potential target for enhancing the efficacy of conventional non-surgical therapy. Cells. 2021;10(5):1–15. doi:10.3390/cells10051169
   Google Scholar
• Ide H, Miyamoto H. The role of steroid hormone receptors in urothelial tumorigenesis. Cancers (Basel). 2020;12(8):2155. doi:10.3390/cancers12082155
   PubMedGoogle Scholar
• Shao X, Guo Y, Xu X et al. The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer. PLoS One, 10(3), e0121535 (2015).
   PubMedGoogle Scholar
• Shao X, Cai J, Zheng Y et al. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer. International journal of clinical and experimental pathology, 8(5), 5309–5317 (2015).
   PubMedGoogle Scholar
• Armamento-Villareal R, Shah VO, Aguirre LE, Meisner AL, Qualls C, Royce ME. The rs4646 and rs12592697 Polymorphisms in CYP19A1 Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds. Front Genet, 7, 211 (2016).
   PubMed Web of Science ®Google Scholar
• Yang X, Jin G, Zhang Y, Xie M. Genetic Variations rs859, rs4646, and rs372883 in the 3’-Untranslated Regions of Genes Are Associated with a Risk of IgA Nephropathy. Kidney & Blood Pressure Research, 44(2), 233–244 (2019).
   PubMedGoogle Scholar
• Slattery ML, Lundgreen A, Herrick JS, et al. Variation in the CYP19A1 gene and risk of colon and rectal cancer. Cancer Causes Control. 2011;22(7):955–963. doi: 10.1007/s10552-011-9768-x
   PubMed Web of Science ®Google Scholar
• Protze J, Naas S, Krüger R, et al. The renal cancer risk allele at 14q24.2 activates a novel hypoxia-inducible transcription factor-binding enhancer of DPF3 expression. J Biol Chem. 2022;298(3):101699. doi: 10.1016/j.jbc.2022.101699
   PubMedGoogle Scholar
• Eliza Lim YY, Yie Sio Y, Say YH, Reginald K, Tim Chew F. Deep intronic 9q21.11 polymorphism contributes to atopic dermatitis risk through methylation regulated expression of tight junction protein 2. Journal of investigational allergology & clinical immunology, 35(3 ), 1 (2023).
   Google Scholar
• Ohhara Y, Tomaru U, Kinoshita I et al. Polymorphisms of the PD-L1 gene 3’-untranslated region are associated with the expression of PD-L1 in non-small cell lung cancer. Genes, chromosomes & cancer, 63(1), e23216 (2024).
   PubMedGoogle Scholar
• Murakami K, Furuya H, Hokutan K, et al. Association of SNPs in the PAI1 gene with disease recurrence and clinical outcome in bladder cancer. Int J Mol Sci. 2023;24(5):4943. doi: 10.3390/ijms24054943
   PubMed Web of Science ®Google Scholar
• Fonteyne V, Ost P, Bellmunt J, et al. Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review. Eur Urol. 2018;73(1):40–50. doi:10.1016/j.eururo.2017.03.019
   PubMed Web of Science ®Google Scholar
• Mancini M, Righetto M, Baggio G. Spotlight on gender-specific disparities in bladder cancer. Urologia. 2020;87(3):103–114. doi:10.1177/0391560319887327
   PubMedGoogle Scholar
• Viswambaram P, Hayne D. Gender discrepancies in bladder cancer: potential explanations. Expert Rev Anticancer Ther. 2020;20(10):841–849. doi:10.1080/14737140.2020.1813029
   PubMed Web of Science ®Google Scholar
• Lao Y, Li X, He L, et al. Association between alcohol consumption and risk of bladder cancer: a dose-response meta-analysis of prospective cohort studies. Front Oncol. 2021;11:696676. doi: 10.3389/fonc.2021.696676
   PubMed Web of Science ®Google Scholar
• Lin Y, Wang Y, Wu Q, et al. Association between obesity and bladder cancer recurrence: a meta-analysis. Clin Chim Acta. 2018;480:41–46. doi: 10.1016/j.cca.2018.01.039
   PubMed Web of Science ®Google Scholar
• Khadhouri S, Gallagher KM, MacKenzie KR et al. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study. Eur Urol Focus, 8(6), 1673–1682 (2022).
   PubMedGoogle Scholar